RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 6 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > FDA Plans Study on Corrective DTC Advertising

FDA Plans Study on Corrective DTC Advertising

Posted 28 February 2012 | By Alexander Gaffney, RAC 

The US Food and Drug Administration (FDA) is calling for a study on corrective direct-to-consumer (DTC) advertising and its impact on correcting misperceptions about a product's safety and efficacy for a given indication.

"FDA regulations require prescription drug advertisements to contain accurate information about the benefits and risks of the drug advertised.  When this is not the case, corrective advertising is designed to dissipate or correct erroneous beliefs resulting from a false claim," says FDA in the Federal Register posting.

FDA's two-phase study will look at message exposure, similarity of original and corrective ads and the length of time between exposure to the original and corrective ad.


Read more:

FDA - Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study: Examination of Corrective Direct-to-Consumer Television Advertising


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe